Allarity Therapeutics Q2 loss narrows as expenses fall

Allarity Therapeutics

14/08/2026 13:10

Overview
Cancer drug developer's Q2 net loss narrowed yr/yr, operating expenses declined
Company ended Q2 with $26.9 mln in cash and restricted cash, up from prior year

Outlook
Company did not provide specific financial guidance or forecasts for the current or future periods

Result Drivers
MANUFACTURING CAMPAIGN COMPLETION - Co completed manufacturing campaign for stenoparib, securing drug supply and supporting late-stage clinical development
CLIA LAB CERTIFICATION - Co obtained CLIA certification for its in-house laboratory, enabling full control of DRP testing to support U.S. clinical trials

Company press release: ID:nGNXNH0pP

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$3.41 mln
 
Q2 Operating Expenses
 
$2.67 mln
 
Q2 Operating Income
 
-$2.67 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Allarity Therapeutics Inc is $10.25, about 653.7% above its August 13 closing price of $1.36

Reuters Recommended Reads
Aug 13 - Denmark's Zealand Pharma H1 revenue, profit fall sharply
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 13 - NuCana Q2 loss narrows as clinical milestones remain on track

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)